This Educational course organised by the ESC Working Group on Thrombosis was held at the European Heart House on 7-9 June 2007.
Directed at clinical and invasive cardiologists, scientists and clinical pharmacologists, this course focuses on the clinical and scientific challenges within the area of coronary thrombosis.
This educational training programme and online resources are supported by unrestricted educational grants from AstraZeneca, Bristol-Myers Squibb, Laboratoires GlaxoSmithKline, Lilly Critical Care Europe/ Daiichi Sankyo Europe, Rottapharm SL, Sanofi-Aventis.
Formats available for download below:
Play webcast
| SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY |
|
|
Welcome and Introduction
R. De Caterina (IT)
|
|
|
Atherothrombosis: Pathophysiological background
R. De Caterina (IT)
|
|
 |
Old and new methods to assess platelet function and resistance to antiplatelet drugs
S.D. Kristensen
|
|
|
SESSION 2: UPDATE IN PHARMACOLOGY AND DEVICES
|
|
Low-dose aspirin, coxibs, NSAIDs and their combination
D. Fitzgerald
|
|
|
New antiplatelet agents
D. Moliterno
|
|
|
Coagulation 2007: sites of action of new inhibitors and monitoring
D. Moliterno
|
|
 |
Stents and devices: trading restenosis for late stent thrombosis?
P-G. Steg (FR)
|
|
|
PPAR-gamma agonists in atherothrombosis
R. De Caterina
|
|
|
Rimonabant
P-G. Steg (FR)
|
|
| SESSION 3: NON-ST ELEVATION ACUTE CORONARY SYNDROMES |
 |
Markers for Risk Stratification
F. Andreotti
|
|
 |
Debate: Conservative strategies in NSTE-ACS - part I
F.W.A. Verheugt
|
|
 |
Debate: Invasive strategies in NSTE-ACS - part II
K. Huber
|
|
|
Debate: discussion |
|
|
Optimal antithrombotic therapy for patients undergoing PCI - unfractionated heparin, low-molecular weight heparins, bivalirudin, GP IIb-IIIa antagonists
S.D. Kristensen
|
|
|
Clopidogrel: how much, how early, for how long? Can we skip GP IIb/IIIa antagonists?
L.H. Rasmussen
|
|
|
SESSION 4: CLOPIDOGREL IN NON-STEMI, STEMI AND PCI: HOW MUCH, HOW EARLY, FOR HOW LONG, WITH OR WITHOUT GP IIB/IIIA ANTAGONISTS?
|
 |
Case presentations
M. Zimarino
|
|
|
Bleeding in ACS: the difficult trade-off for thrombosis prevention
F. Andreotti
|
|
|
Triple anti-thrombotic therapy with aspirin, clopidogrel and vitamin K antagonists: rationale and risk
S. Husted
|
|
|
SESSION 5: ACUTE ST-ELEVATION MYOCARDIAL INFARCTION
|
|
Pre-hospital thrombosis
G. Steg
|
|
|
Organizational models for primary PCI
K. Huber
|
|
|
Cath lab therapy in STEMI
S.D. Kristensen
|
|
|
PCI facilitation: forget it - forget me not...
F.W. Verheugt
|
|
| SESSION 6: ATRIAL FIBRILLATION |
|
|
Warfarin, aspirin and clopidogrel: lessons from ACTIVE-W
R. De Caterina
|
|
|
Dabigatran, idraoarinux, oral FXa inhibitors
S. Husted
|
|
|
ACE-inhibitors and sartans in AF
L.H. Rasmussen
|
|
|
SESSION 7: FUTURE DEVELOPMENTS
|
|
Stem cells in cardiovascular therapy: Background biology and critical issues
J.F. Martin
|
|
|
Stem cells in cardiovascular therapy: a critical reading of clinical trials
S. Janssens
|
|